Brand mark

Patients with DRAVET SYNDROME deserve a giant leap forward.

There is an urgent need for continued
research to help provide:

Continued research in Dravet syndrome can help deliver meaningful, consistent, and sustained seizure reduction

Meaningful, consistent, and sustained seizure reduction

Learn More
Continued research in Dravet syndrome can help reduce cognitive decline and long-term disability

Improvements to reduce cognitive decline and long-term disability in patients

Learn More
Continued research in Dravet syndrome can help increase patient and caregiver quality of life

Increased patient and caregiver quality of life

Learn More

Watch this video to learn more about Dravet syndrome.

Dravet Syndrome Overview

Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy with onset in infancy and serious neurodevelopmental, motor, cognitive, and behavioral consequences that persist into adulthood.1,2

The prevalence of Dravet syndrome is 1 in 15,700 people in the United States

The number of infants born with Dravet syndrome in the United States3

Seizures associated with Dravet syndrome:1

Seizure activity begins within the first year of life in patients with Dravet syndrome

Begin within the first year of life

Prolonged seizure activity lasting more than 5 minutes is sometimes experienced by patients with Dravet syndrome

Can be prolonged—sometimes lasting more than 5 minutes
(status epilepticus)

The presentation of seizure activity associated with Dravet syndrome can occur in developmentally normal infants

Present in a developmentally normal infant

The impact of Dravet syndrome differs from patient to patient, with seizure frequency and severity, cognitive and behavioral skills, and response to treatment varying widely and evolving over time.1,2,4

For additional information about Dravet syndrome, please visit Dravet Syndrome Foundation (DSF) at The mission of Dravet Syndrome Foundation is to aggressively raise funds for Dravet syndrome and related epilepsies; to support and fund research; to increase awareness; and to provide support to affected individuals and families.


Early diagnosis (preferably within the first 2 years of life), aided by genetic testing, may lead to improved seizure control and cognitive and behavioral outcomes over the long term.4

85% of patients with Dravet syndrome carry an SCN1A gene mutation

The approximate percentage of children diagnosed with Dravet syndrome who carry SCN1A gene mutations4

Because children with Dravet syndrome may not show symptoms at birth, their condition often can go undiagnosed or misdiagnosed for months.

Misdiagnosis can lead to use of inappropriate treatment. Sodium channel blockers such as carbamazepine, oxcarbazepine, lamotrigine, and phenytoin can actually exacerbate seizures in Dravet syndrome.2,4

Sign up for more information about Dravet syndrome

Get updates and important information about Dravet syndrome.

* indicates required field.

Please fill out all fields above.
The email and its confirmed do not match.